South San Francisco, CA April 18, 2023 Press Release Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study In the first-ever positive Phase III…
Tag: TECENTRIQ
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
South San Francisco, CA March 31, 2022 Press Release SKYSCRAPER-02, the first randomized study of tiragolumab in extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival ES-SCLC is a hard-to-treat disease and Tecentriq plus…
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer
South San Francisco, CA September 5, 2018 Press Release Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from its broad clinical development program across different types of lung cancer will be…
Genentech’s TECENTRIQ in Combination with Chemotherapy Helps Patients With Small Cell Lung Cancer
South San Francisco, CA June 30, 2018 Press Release Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy –IMpower133 is the first Phase III study with an immunotherapy-based…
Phase III IMpower150 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung Cancer
South San Francisco, CA November 29, 2017 Genentech Press Release – Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) – SOUTH SAN FRANCISCO, CA — 2017-11-19 00:00:00 Genentech,…
FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
South San Francisco, CA April 17, 2017 Press Release Genentech First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy — SOUTH SAN FRANCISCO, CA —…
Genentech’s Cancer Immunotherapy TECENTRIQTM (Atezolizumab) Shows Promising Results
South San Francisco, CA September 1, 2016 Genentech Press Release Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQTM (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy TECENTRIQ showed significant improvement…